Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 18/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271041 | 0.70 | — | — | |
| SCHEMBL7014760 | 0.67 | KDM5B (0.50) | KDM5B | |
| SCHEMBL2272058 | 0.62 | KDM5B (0.45) | KDM5BLMNAMAPK1L3MBTL1 | |
| SCHEMBL17784391 | 0.56 | KDM5B (0.43) | KDM5BLMNAMAPK1L3MBTL1 | |
| SCHEMBL16432965 | 0.54 | KDM5B (0.49) | KDM5B | |
| SCHEMBL2270862 | 0.52 | — | — | |
| SCHEMBL2270859 | 0.52 | — | — | |
| SCHEMBL7500298 | 0.48 | CYP3A4 (0.42) | — | |
| SCHEMBL19410849 | 0.48 | KDM4E (0.32) | KDM5B | |
| SCHEMBL313808 | 0.48 | MASP2 (0.44) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347252-A2 | Method of treating cachexia and certain new compounds for use in this method | SANKYO COMPANY LIMITED (JP) | 1989-12-20 | — | — | EP | claimed |
| US-10745673-B2 | Heme protein catalysts for carbon-boron bond formation in vitro and in vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2488528-A1 | PYRROLO [3,2 -E][1,2,4]TRIAZOLO [1,5-A]PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | Senexis Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2488527-A1 | PYRROLO [3, 2 -E][1,2,4]TRIAZOLO [1,5 -A]PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | Senexis Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011042497-A1 | PYRROLO [3,2 -E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042496-A1 | PYRROLO [3, 2 -E] [1,2,4] TRIAZOLO [1,5 -A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| EP-0347252-A2 | Method of treating cachexia and certain new compounds for use in this method | SANKYO COMPANY LIMITED (JP) | 1989-12-20 | — | — | EP | disclosed |
| EP-0101517-A1 | NOVEL s-TRIAZOLE(1,5-a)PYRIMIDINE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745673-B2 | Heme protein catalysts for carbon-boron bond formation in vitro and in vivo | HMBS, PPOX, MB | KDM5B 2642/4885LMNA 1942/4885MAPK1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.